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Abstract
A long-term research programme has been underway in Ireland to evaluate the usefulness of badger vaccination as part of
the national bTB (bovine tuberculosis) control strategy. This culminated in a field trial which commenced in county Kilkenny
in 2009 to determine the effects of badger vaccination on Mycobacterium bovis transmission in badgers under field
conditions. In the present study, we sought to optimise the characteristics of a multiplex chemiluminescent assay for
detection of M. bovis infection in live badgers. Our goal was to maximise specificity, and therefore statistical power, during
evaluation of the badger vaccine trial data. In addition, we also aimed to explore the effects of vaccination on test
characteristics. For the test optimisation, we ran a stepwise logistic regression with analytical weights on the converted
Relative Light Units (RLU) obtained from testing blood samples from 215 badgers captured as part of culling operations by
the national Department of Agriculture, Food and the Marine (DAFM). The optimised test was applied to two other datasets
obtained from two captive badger studies (Study 1 and Study 2), and the sensitivity and specificity of the test was attained
separately for vaccinated and non-vaccinated badgers. During optimisation, test sensitivity was maximised (30.77%), while
retaining specificity at 99.99%. When the optimised test was then applied to the captive badger studies data, we observed
that test characteristics did not vary greatly between vaccinated and non-vaccinated badgers. However, a different time lag
between infection and a positive test result was observed in vaccinated and non-vaccinated badgers. We propose that the
optimized multiplex immunoassay be used to analyse the vaccine trial data. In relation to the difference in the time lag
observed for vaccinated and non-vaccinated badgers, we also present a strategy to enable the test to be used during trial
evaluation.
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Introduction
Badgers play an important role in the epidemiology of bovine
tuberculosis (bTB) in Ireland, by acting as a source of infection to
cattle [1,2]. The prevalence of Mycobacterium bovis infection in
badgers, based on animals captured as part of culling operations
by the national Department of Agriculture, Food and the Marine
(DAFM), was estimated recently at 36.3% [3], although this is
known to vary substantially between areas where bTB in cattle is
problematic [4] or absent [5]. Sustainable progress towards
eradication of M. bovis infection in cattle might not be possible
in the face of continued spillover of infection from badgers to cattle
[2].
Several control options are available to limit transmission of
infection from badgers to cattle, including reducing the frequency
of contact between these species and decreasing the proportion of
the badger population susceptible to infection, through vaccina-
tion [2]. In Ireland, focused badger culling is being used to reduce
contact rates between badgers and cattle in areas of high bTB
incidence in cattle. However, it is hoped that badger culling can be
replaced by, or supplemented with, badger vaccination. A long-
term Irish research programme is on-going to evaluate the
usefulness of badger vaccination as part of the national bTB
control strategy. A series of pen-based vaccination trials have been
conducted, where badgers were vaccinated with Bacillus Calmette-
Guerin (BCG) and subsequently challenged with M. bovis, and the
impact of vaccination on pathology, bacteriology and progression
of infection in badgers has previously been reported [6–9].
Subsequent to this work, a field trial commenced in county
Kilkenny, in 2009, to determine the effects of badger vaccination
on M. bovis transmission in badgers under field conditions [10].
The field trial design will enable comparison of bTB incidence
between vaccinated and unvaccinated badgers in three areas of
differing vaccine coverage (100, 50 and 0%).
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A number of challenges have been encountered during the
design of the field trial in Co. Kilkenny, including: a) the need to
fully understand the biology underpinning protection following
BCG vaccination, both in individual badgers and within the
broader badger population (including the likelihood of reduction
of infectiousness and therefore transmission); b) the need to
identify the infection status of each badger at each capture event (a
capture/recapture design has been employed), and c) the need for
sufficient statistical power in the aforementioned design. There is
now a better understanding of options to address the first and third
of these challenges [10,11]. In this paper, we consider the second
of these challenges, that is, the need for a test to identify the
infection status of individual badgers at each capture event. It has
been shown recently that this diagnostic test will need a specificity
very close to 100% in order to obtain sufficient study power [11].
The authors estimated a minimum specificity of 99.8% to achieve
a power above 60% in this trial. The need for a high specificity
reflects the fact that the cost of false positive test results is much
higher than that of false negative results.
A significant amount of work in relation to diagnostic methods
for tuberculosis in live badgers has been conducted in Ireland and
the United Kingdom [12–17]. Assays based on the measurement
of cellular responses, such as gamma-interferon, have attracted
considerable interest as they are expected to deliver a higher
sensitivity in comparison to antibody-based assays [13,15].
Furthermore, these cell response assays have the advantage of
being able to detect earlier stages of infection [18]. However, one
of the drawbacks of these assays is the large effect of pre-culture
holding time and temperature on gamma-interferon responses
[19,20]. Several other bTB assays have been developed. The
Brock test is an indirect ELISA that measures M. bovis-specific
antibody responses to a single antigen, MPB83 [21,22]. MPB83 is
expressed by other members of M. tuberculosis complex, but is
serodominant in M.bovis infection. Subsequent studies have shown
that test sensitivity and specificity can be enhanced by using a
mixture of antigens rather than a single antigen. Based on the use
of a multi-antigen print immunoassay (MAPIA) and culture as the
gold standard, the sensitivity was found to increase from 47.4% to
52.6% and the specificity from 89% to 95% [23]. In an attempt to
simplify the procedure, thereby allowing badger testing to be
performed in the field, a lateral flow immunoassay (the Brock TB
Stat-Pak assay; Chembio Diagnostic Systems, Inc., Medford, NY)
was developed [14,16].
Here, we will look at the Enfer chemiluminescent multiplex
ELISA system, originally developed for testing M. bovis in cattle
[24,25]. The test was adapted for badgers and applied to 200
blood samples from badgers captured in Ireland in areas of high
bovine tuberculosis prevalence [26], this study reported a
sensitivity and specificity in badgers of 56.7% and 96.99%,
respectively, when using a panel of M. bovis antigens. The
availability of this test, the fact that this test can be performed in
stored blood samples without losing sensitivity or specificity, and its
quantitative nature, made this test the test of choice. Given this
background, the current study had two objectives. First, we sought
to statistically optimise a multiplex chemiluminescent assay for
detection of M. bovis infection in live badgers to maximise
specificity, and therefore statistical power, during evaluation of
the badger vaccine trial in Ireland. Second, we aimed to explore
the effects of vaccination on test characteristics and to review the
implications for analysis of the data from the Kilkenny badger
vaccine trial.
Materials and Methods
The 215 blood samples used for test optimization were part of
an archive. The badgers from which these samples had been
taken, had been captured as part of the DAFM culling operations
carried out in the Republic of Ireland. The Department of Arts,
Heritage and the Gaeltacht, specifically the National Parks and
Wildlife Service, issues licences to the Department of Agriculture,
Food and the Marine to undertake the capturing programme. The
captive badger studies were carried out under license (No. B100/
3187, Cruelty to Animals Act 1876) issued by the Department of
Health and Children, and ethical approval was obtained from the
UCD Animal Research Ethics Committee (AREC-P-04-28 and
AREC-P-24-06).
1. Test optimisation using naturally infected wild badgers
1.1 Samples. Serum samples from 215 badgers captured as
part of the DAFM culling operations carried out in the Republic of
Ireland were used for optimisation of the diagnostic test. Focused
(reactive) badger removal is conducted under license in the vicinity
of herds that have had a severe bTB breakdown where the cause
cannot be attributed to non-wildlife sources. The serum samples
had been collected for archiving purposes. A study by Murphy et
al. (2010) [3] looked at these badgers for gross visible lesions of TB
at post mortem and samples were collected from a range of tissues
and pooled into groups for bacterial culture of M. bovis. An aseptic
technique was used when preparing tissue samples to minimize
contamination before culture. In the current study, culture results
were used as the gold standard and a badger was considered
infected when M. bovis was isolated from any of the samples taken.
1.2 Multiplex immunoassay. Antibody responses, ex-
pressed as relative light units (RLU), to a panel of antigens were
measured using the Enfer chemiluminescent multiplex ELISA
system (Enfer Scientific, Co. Kildare, Ireland). The antigen panel
consisted of the following six recombinant proteins: MPB83,
MPB70, Rv3616c fragment and full protein, ESAT-6 and CFP10,
as well as purified protein derivative from M. bovis (PPDb) and a
peptide of MPB70. Tests were carried out by Enfer Scientific using
96-well microtitreplates. Recombinant antigens (Fusion Antibodies
Ltd. (Belfast)) and peptides (Genosphere Biotechnologies (France))
were prepared as previously described by Whelan et al. (2008)
[24].
The multiplex assay was carried according to Whelan et al.
(2008) [24]. Serum samples were diluted 1:450 into sample
dilution buffer and mixed. A 50 ml sample dilution was added per
well. The plates were incubated at room temperature with
agitation for 90 minutes. The plates were washed once with Enfer
Wash Buffer (Enfer Scientific) and aspirated. The detection
antibody (CF2/HRPo Anti-Badger IgG-HRP conjugate, kindly
provided by Mark Chambers, AHVLA, Weybridge, UK) was
prepared to a dilution of 1:75,000 in detection antibody dilution
buffer. After addition of 50 ml of the detection antibody to each
test well, the plates were incubated at room temperature for
30 minutes with agitation. The plates were washed as above and
50 ml of chemiluminescent substrate (50:50 substrate and diluent)
was added per well. Signals were captured and data were extracted
and analysed as previously described [24].
1.3 Data analyses. The 8 antibody response RLU-signals
were blank-corrected by subtracting a blank spot signal specific to
each sample. Initially, all zero or negative test-result values were
converted to 0.0001 to allow for logarithmic transformation;
however, the logarithmic transformation did not improve ROC
curves. The blank-corrected values with negative values converted
to 0.0001 will be referred to as ‘‘converted RLU’’. Descriptive
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statistics (mean, standard deviation, minimum, maximum and
median) of the converted RLU to the 8 antigens were calculated
separately for non infected (NI) and infected (I) badgers. ROC
curves for each antigen were constructed, and the ROC curve
showing the largest sensitivity, with specificity set at 99.99%, is
presented in this manuscript.
A stepwise logistic regression, with culture status as the
dependent variable, the converted RLU to each of the 8 antigens
as the independent variables, and using a significance level of 0.05,
was carried out. Analytical weights were used to account for the
cost of false positive test results being higher than that of negative
test results. After exploring different cost ratios, a cost ratio of
100:1 (false positive: false negative) was selected. Cost ratios higher
than 100:1 did not improve the ROC curve. From the logit
obtained after using logistic regression, a cut off was chosen that
allowed sensitivity to be maximised for specificity equal to 99.99%.
A Hosmer-Lemeshow test was used to assess the goodness of fit of
the final model. For the best linear combination of antigens, a
ROC curve was created. All analyses were performed using Stata
version 12 (Stata Corp, College Station, TX, USA).
2. Evaluation of test characteristics in vaccinated and
non-vaccinated captive badgers
2.1 Study 1 samples. Serum samples were available from a
laboratory vaccine trial (Study 1). This trial was conducted to
compare the levels of protection between vaccinated and non-
vaccinated badgers, and between badgers vaccinated with different
vaccines. Briefly, badgers were sourced from an area free of bTB
and allowed to adapt to captivity for 12 weeks prior to the start of
the experiment. During adaptation, the badgers were screened for
tuberculosis using a lymphocyte transformation assay (LTA). The
experiment consisted of three groups of badgers: animals
vaccinated (108 CFU) with either BCG Danish 1331 (n= 8
animals) or BCG Pasteur 1173P2 (n = 7), and controls (n = 8).
All badgers were challenged by the endo-bronchial route with
66103 CFU M. bovis. The badgers were euthanised 15 weeks post-
challenge and subjected to a detailed post-mortem examination.
Blood samples were taken twice a month prior to vaccination (6
samples per badger) and once a month subsequently (2 samples
prior and 4 samples subsequent to challenge, per badger).
2.2 Study 2 samples. Serum samples were also available
from a second captive badger study (Study 2). Data were available
from a group of 9 badgers that were vaccinated (108 CFU, BCG
Danish strain) and a group of 10 badgers that served as a control
group. Badgers were challenged with 36102 CFU of M. bovis by
the endo-bronchial route, and followed for 51 weeks after
challenge. Blood samples were taken every two weeks before
badgers were vaccinated (3 samples per badger) and once a month
subsequent to vaccination (3 samples before and 10 samples after
challenge per badger) with a further sample taken before badgers
were euthanized three months later.
2.3 Multiplex immunoassay. The assay was conducted as
described previously.
2.4 Data analysis. For each of the captive studies, descriptive
statistics of the antibody responses to each of the 8 antigens were
calculated independently for each of the following badger
categories: non-vaccinated – non-infected (Category 1), vaccinated
– non-infected (Category 2), non-vaccinated - infected (Category 3)
and vaccinated - infected (Category 4). In Study 1, the descriptive
analysis was done taking into account only those badgers
vaccinated with the Danish strain and then repeated using data
from both groups of vaccinated badgers (Danish and Pasteur).
The optimal antigen combination (described in section 2.1) was
applied to the data from Study 1 and Study 2 resulting in
estimated logits; by applying the selected cut-off to the logits
obtained, the sensitivity and specificity of the multiplex immuno-
assay test was estimated separately for each of the studies. In order
to be consistent, only samples from badgers vaccinated with the
Danish strain were used for estimating sensitivity and specificity in
Study 1.The sensitivity and specificity was also estimated
separately for vaccinated and non-vaccinated badgers in Study
2. Badgers in these datasets were considered infected one day after
they had been challenged. For Study 2 data, the probability of
testing positive was calculated from the logit using the formula:
prob= exp(logit)/(1+exp(logit)). The cut-off value was also con-
verted into a probability using the same formula. Scatter plots of
the probability of testing positive by time since the start of the trial
and least squares means of these probabilities were created
separately for the control and vaccinated groups in Study 2. In
order to explore whether the logit was associated with time since
infection, a generalized estimating equations model (GEE; to
account for repeated measures within a badger) with a vaccina-
tion-time interaction term was conducted. The model used a
Gaussian distribution with identity link and exchangeable corre-
lation structure. Quadratic and logarithmic transformations of the
independent variable ‘‘time since challenge’’ were carried out but
did not yield lower values of QIC (quasilikelihood under the
independence model criterion). The working correlation for the
repeated effect was 0.288. A two-way graph was created using the
predictions of the GEE model and time since infection by
vaccination status. All statistics were carried out using Stata
version 12 (Stata Corp, College Station, TX, USA).
Results
1. Test optimisation
In total, 78 of the 215 samples (36.3%) were infected with M.
bovis based on culture results. Descriptive statistics for converted
RLU response to each of the 8 antigens by infection status are
presented in Table 1.
When using stepwise logistic regression with analytic weights, 7
of the 8 antigens were retained in the final model, but MPB70
peptide was not. The Hosmer-Lemeshow test showed that the
model fitted the data sufficiently well (p-value 0.29). Figure 1
depicts the ROC curve of the logit obtained for the combination of
antigens. For a specificity of 99.99%, a logit cut-off of 22.67 was
needed. At this cut-off, the sensitivity was 30.77%. Of the single
antigens, MPB83 achieved the largest sensitivity, 24.36%, with the
specificity set at 99.99% (Figure 1).
2. Evaluation of test characteristics in vaccinated and non
vaccinated badgers
In Study 1, 258 samples were analysed, with 30% of the badgers
being tested 11 times and 70% of them 12 times. In Study 2, 297
samples were analysed (two samples could not be analysed for
Rv3616c (fragment) due to insufficient serum, and were removed
from the study), with a mean of 15.6 samples per badger (min= 9,
max= 17). A table showing the descriptive statistics for each of the
8 antigens as converted RLU, by infection and vaccination status,
is presented as (Table S1). This file also presents data for Study 1
samples originating from badgers vaccinated with the Danish
strain.
Using the optimal antigen combination, the mean sensitivity
and specificity of the multiplex immunoassay test were respectively
22.99% (CI:14.64–33.25%) and 78.95% (CI:72.07–84.80%) for
Study 1, and 33.51% (CI:26.76–40.81%) and 83.04% (CI:
74.78%–89.47) for Study 2. The sensitivity and specificity were
also calculated separately for vaccinated and non-vaccinated
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badgers from Study 2, obtaining sensitivity values for vaccinated
badgers of 32.26 (CI:22.93–42.75%) and specificity of 88.89%
(CI:70.84–97.65%); the equivalent values for non-vaccinated
badgers were 34.78% (CI:25.15–45.43%) sensitivity and 81.18%
(CI:71.24–88.84%) specificity.
Figure 2 presents scatter plots and least square means of the
probability of testing positive for the control and vaccinated groups
in Study 2 by time since the start of the study.
A two-way graph showing the GEE predictions by time since
challenge is presented in Figure 3. In this Figure, the rate of
increase of the logit is presented separately for vaccinated and non-
vaccinated badgers. The GEE analysis showed a significant
association of the dependent variable with all three independent
variables: time since challenge, vaccination and their interaction
term (p,0.005). When a robust GEE model was fitted, the
interaction term was borderline significant (p = 0.045). In the
Figure, a line showing the selected cut off value is highlighted. A
reference line showing the minimum number of days to test
positive for infected non-vaccinated badgers is also presented.
Discussion
The main objective of this paper was to optimise a diagnostic
test for M. bovis infection in live badgers, for use during the
evaluation of vaccine efficacy in a large bTB vaccine field trial in
Ireland. On most occasions when a test is being developed, it is
desirable to optimise both the sensitivity and the specificity of the
test; in such situations, a cost ratio for false positives and false
negatives of 1:1 is selected. However, in a previous study focusing
on the statistical power of this trial [11], it was demonstrated that
the diagnostic test needed to be tailored to achieve a specificity
close to 100% to achieve a reasonable statistical power (60–80%).
As the incidence of M. bovis infection in the badger population
decreases, there will be an increasing number of false positive
results, randomly occurring in the mainly negative samples from
both vaccinated and unvaccinated animals, with the potential to
greatly bias estimates of vaccine efficacy. Hence, the need for
specificity close to 100%, thereby minimising the number of false
positive results. Greiner et al. (2000) [27] have shown that analytic
weights can be used to optimise cut-off values with regard to a
specific cost ratio of false positive and false negative results. In
order to reduce the number of false positive results, the upper left
corner of the ROC curve (draw as sensitivity against 1-specificity)
was optimised by selecting a cost ratio of false positives to false
negatives equal to 100:1. Other ratios were explored, noting that
cost ratios higher than 100:1 did not improve the ROC curve,
probably due to the relatively small number of samples available to
test. Subsequently, a cut-off value of a logit equal to 22.67 was
needed to achieve a specificity of 99.99%, resulting in a maximum
sensitivity of 30.77%. This sensitivity, although quite low in
comparison to generally available diagnostic tests, is sufficient to
achieve a statistical power of the vaccine trial of over 80% [11]. In
this trial, test sensitivity is of lesser importance on study power
because, when the incidence of M. bovis infection in badgers is low,
the expected proportion of false negatives will be a fraction of
something that is already a very small proportion.
In this study, culture was used to ascertain the disease status of
individual badgers. Although it is unlikely that culture is a perfect
‘gold standard’, the methodology used in this study is based on an
enhanced post mortem technique, currently the most sensitive
available. In recent years, a progressive increase in estimated
prevalence of M. bovis infection in badgers has been observed, both
in Ireland and the UK, attributable to improved sensitivity of
detection [3,4]. Crawshaw et al. (2008) [28] reported a 54%
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sensitivity of a standard post-mortem procedure compared to a
more detailed enhanced post mortem technique.
A second objective in this paper was to assess the effects of
vaccination on test characteristics. The optimised test described
above was applied to data from Study 1 and 2. Badgers in Study 2
were followed for a much longer period of time subsequent to
challenge than badgers in Study 1. Therefore data from Study 2,
as opposed to Study 1, were used for further analysis. The
sensitivities/specificities for non- vaccinated and vaccinated
badgers in Study 2 were 34.78/77.97% and 32.26/88.68%,
respectively. The test characteristics for both vaccinated and non-
vaccinated badgers were very similar, as indicated by the overlap
of the confidence intervals. Nonetheless, the specificity obtained
for Study 2 was lower than that obtained when the test was
optimised in naturally infected individuals (99.99%). When looking
at the specific badger data presented in Figure 2, it was observed
that a large proportion of the false positives samples within the
control group badgers belonged to two badgers that repeatedly
Figure 1. ROC curves of the logit obtained using either the optimised combination of antigens (blue line) or MPB83 (red line). Each is
based on converted RLU values, and the green line is included for reference.
doi:10.1371/journal.pone.0100139.g001
Figure 2. Scatter plot and least square means of the probability of testing positive for the control (left graph) and vaccinated (right)
groups in Study 2 by time since the start of the study. Vertical reference lines showing the day of vaccination and challenge, and a horizontal
reference line of the cut-off are included.
doi:10.1371/journal.pone.0100139.g002
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tested positive prior to challenge (6 and 4 times per badger
respectively, out of a total of 6 sampling times during this period).
One possibility is that those two badgers were infected prior to the
start of the experiment. However, blood samples from these
animals were repeatedly screened before challenge by the more
sensitive lymphocyte transformation assay using bovine and avian
tuberculins, and were negative on all occasions (data not shown).
The underlying cause of the false positive reactions in the two
badgers is unknown though cross reactivity can potentially arise
from concurrent infections with related pathogens or any microbe
with shared epitopes, all of which potentially influence the
specificity of this test. By removing samples from those two
badgers, the specificity of the test increased to 93.62% in non-
vaccinated badgers and to 91.00% for all badgers (vaccinated and
non-vaccinated combined). Contrary to the control group, the
false positives samples observed in the vaccinated group belonged
to different badgers. These badgers tested positive (prior to
challenge) on no more than one occasion, out of an average of 6
tests per badger during this period.
One of the concerns of serologically-based assays is that they
detect infection later than assays based on the cell-mediated
immune response, such as gamma-interferon. This is because the
initial immune response is cell-mediated. A lag between infection
and positive test results has been observed in the data obtained
from Study 2 (Figures 2 and 3); this lag varies between vaccinated
and non-vaccinated animals. From a biological point of view, we
would expect that non-vaccinated badgers will carry a larger
antigen load and thus will mount a larger antibody response to M.
bovis challenge than those that are vaccinated. Nonetheless, it is the
vaccinated group that shows the earliest positive test when a cut-
off =22.67 is selected (Figure 3 shows samples of vaccinated
badgers testing positive earlier than 100 days after challenge, while
the equivalent for the non-vaccinated group was 215 days). We
can think of two possible interpretations for the observed results,
one is that vaccinated badgers will mount a serological response
faster than non-vaccinated badgers following infection, the other
option is that observed results are due to chance (due to the small
number of badgers in each group). It is possible that some of the
badgers that were randomly allocated to the vaccinated group
were extremely susceptible to infection and for those badgers,
vaccination did not work.
Considering all of the above, what we propose in this study is
that the multiplex immunoassay can be used to analyse the vaccine
trial data, incorporating the optimal antigen combination identi-
fied from section 2.1 and a consistent cut-off of -2.67. To account
for the differences observed in the lag between time of infection
and a positive test, we recommend that only subsequent captures
that occur more than ‘‘Y’’ days apart are used for the analysis,
with ‘‘Y’’ being the minimum number of days necessary between
infection and a subsequent positive test (215 days in this study).
The number ‘‘Y’’ can be determined, after the vaccine trial dataset
is gathered, as a trade-off between the increase in sensitivity and
the possible reduction in power resulting from a decrease of our
sample size. By taking this approach, it will be possible to minimise
bias, specifically the incorrect classification of infected animals as
non-infected.
In summary, a multi-antigen test has been optimised for use
during the evaluation of vaccine effectiveness in a badger bTB
vaccine field trial in Ireland. During optimisation, test sensitivity
was estimated, while specificity was set at 99.99%. Based on the
operating characteristics of the diagnostic test, it has been
demonstrated that the statistical power of the field trial could
exceed 80% [11]. We have also observed that test characteristics
do not vary greatly between vaccinated and non-vaccinated
badgers. In relation to the time lag between infection and a
positive test in vaccinated and non-vaccinated badgers, we have
presented a strategy to enable the test to be used, and applied
consistently, during trial evaluation.
Supporting Information
Table S1 Mean, standard deviation, maximum and
median values for converted RLU response to each of
Figure 3. GEE predictions by time since challenge for vaccinated and non-vaccinated badgers. Two reference lines are presented: a
vertical line showing the minimum number of days to test positive for infected non-vaccinated badgers and a horizontal cut-off line.
doi:10.1371/journal.pone.0100139.g003
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the 8 antigens, by infection and vaccination status
(Categories 1 to 4).
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